Pfizer says antiviral pill cuts risk of severe COVID-19 by 89%

1 Oct 04:37 Key points summarised by AI

Pfizer's experimental antiviral pill, Paxlovid, significantly cut the risk of hospitalization or death by 89% for high-risk adult COVID-19 patients in a clinical trial.
The trial was stopped early due to the drug's overwhelming efficacy, which appears to surpass results seen with Merck's competing molnupiravir pill.
Pfizer plans to submit interim trial results to the U.S. Food and Drug Administration (FDA) for emergency use authorization for Paxlovid, a combination treatment taken twice daily.
The drug, a protease inhibitor, works by blocking an enzyme the coronavirus needs to multiply, offering a vital oral treatment option for early-stage COVID-19.

Six injured after car smashes into On Nut shopping mall

Yesterday 22:44 Key points summarised by AI

A 67-year-old woman drove her car through the glass frontage of a Bangkok shopping mall, injuring six people, including a six-year-old girl.
The driver claimed she accidentally pressed the accelerator instead of the brake after being startled, causing the vehicle to surge forward.
She apologized to the victims, promising insurance coverage and additional financial aid, while police continue to gather statements before filing charges.